// App-Quantinova.ai

OC 73.1 : Updated Main Study Period and Long-Term Extension (LTE) Results With Oral Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Immune Thrombocytopenia (ITP)

Researchers

Presenter

  • D. Kuter

Principal Investigators

  • M. Efraim

  • Z. Kaplan

  • J. Mayer

  • P. Choi

  • A. Jansen

  • V. McDonald

  • R. Baker

  • R. Bird

  • M. Garg

  • J. Gumulec

  • M. Kostal

  • W. Ghanima

  • M. Yao

  • N. Cooper

Medical Centers

  • Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts, United States

  • Multiprofile Hospital for Active Treatment Sv. Marina , Varna, Bulgaria

  • Monash Medical Centre, Melbourne, Australia

  • Masaryk University Hospital, Brno, Moravskoslezsky kraj, Czech Republic

  • The Canberra Hospital, Gastroenterology, Woden, Australian Capital Territory, Australia

  • Transplantation, Erasmus MC, University Medical Center, Rotterdam, Netherlands

  • Barts Health NHS Trust, The Royal London Hospital, London, United Kingdom

  • WA Centre of Thrombosis and Haemostasis (WACTH) Centre for Computational and Systems Medicine, Murdoch University; Perth Blood Institute., Perth, Western Australia, Australia

  • Princess Alexandra Hospital, Woolloongabba, Australia

  • Leicester Royal Infirmary, Leicester, England, United Kingdom

  • University Hospital Ostrava and Faculty of Medicine University of Ostrava, Ostrava, Moravskoslezsky kraj, Czech Republic

  • University Hospital of Hradec Kralove, Hradec Kralove, Kralovehradecky kraj, Czech Republic

  • University of Washington Health Sciences, Seattle, Washington, United States

  • Ostfold hospital, Sarpsborg, Ostfold, Norway

  • Sanofi US Services Inc., Bridgewater, New Jersey, United States

  • Hammersmith Hospital, London, England, United Kingdom

  • Sanofi Genzyme, Cambridge, MA, United States

Locations

  • United States

  • Bulgaria

  • Australia

  • Czech Republic

  • Netherlands

  • United Kingdom

  • Norway

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Immune thrombocytopenia

Biomarkers

  • N/A

Drug/Treatment

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I/II

Study Id's

  • NCT03395210

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved